View Item 

Show simple item record

Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study

dc.contributor.authorHelfrich, Y. R.en_US
dc.contributor.authorKang, S.en_US
dc.contributor.authorHamilton, Ted A.en_US
dc.contributor.authorVoorhees, John J.en_US
dc.date.accessioned2010-06-01T22:14:48Z
dc.date.available2010-06-01T22:14:48Z
dc.date.issued2007-08en_US
dc.identifier.citationHelfrich, Y.R.; Kang, S.; Hamilton, T.A.; Voorhees, J.J. (2007). "Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study." British Journal of Dermatology 157(2): 369-374. <http://hdl.handle.net/2027.42/75262>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75262
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17596167&dopt=citationen_US
dc.format.extent160553 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal Compilation 2007 British Association of Dermatologistsen_US
dc.subject.otherBecocalcidiolen_US
dc.subject.otherCalcipotriolen_US
dc.subject.otherPsoriasis Vulgarisen_US
dc.subject.otherRandomized Controlled Trialen_US
dc.titleTopical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid17596167en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75262/1/j.1365-2133.2007.08037.x.pdf
dc.identifier.doi10.1111/j.1365-2133.2007.08037.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceBikle DD, Ng D, Tu CL et al. Calcium- and vitamin D-regulated keratinocyte differentiation. Mol Cell Endocrinol 2001; 177: 161 – 71.en_US
dc.identifier.citedreferencevan de Kerkhof PCM. An update on vitamin D 3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11: 2 – 10.en_US
dc.identifier.citedreferenceKang S, Yi S, Griffiths CEM et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138: 77 – 83.en_US
dc.identifier.citedreferenceKragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D 3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988; 119: 223 – 30.en_US
dc.identifier.citedreferenceDubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27: 983 – 8.en_US
dc.identifier.citedreferenceHighton A, Quell J. Calcipotriene ointment 0·005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995; 32: 67 – 72.en_US
dc.identifier.citedreferenceHarrington CI, Goldin D, Lovell CR et al. Comparative effects of two different calcipotriol (MC903) formulations vs. placebo in psoriasis vulgaris: a randomized, double-blind, placebo-controlled, parallel group multicentre study. J Eur Acad Dermatol Venereol 1996; 6: 152 – 8.en_US
dc.identifier.citedreferenceKragballe K, Gjertsen BT, de Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193 – 6.en_US
dc.identifier.citedreferenceBourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993; 129: 74 – 6.en_US
dc.identifier.citedreferenceHoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235: 281 – 2.en_US
dc.identifier.citedreferenceBourke JF, Mumford R, Whittaker P et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997; 37: 929 – 34.en_US
dc.identifier.citedreferenceBleiker TO, Bourke JF, Mumford R et al. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol 1998; 139: 285 – 6.en_US
dc.identifier.citedreferenceFogh K, Kragballe K. Recent developments in vitamin D analogs. Curr Pharm Des 2000; 6: 961 – 72.en_US
dc.identifier.citedreferenceAshcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320: 963 – 7.en_US
dc.identifier.citedreferenceWitman P. Topical therapies for localized psoriasis. Mayo Clin Proc 2001; 76: 943 – 9.en_US
dc.identifier.citedreferencePDR Drug information for Dovonex ointment 0·005%. Physicians’ Desk Reference. Available at: http://www.drugs.com/pro/dovonex-ointment.html ( accessed 2 June 2007 ).en_US
dc.identifier.citedreferencePlum LA, Prahl JM, Ma X et al. Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 2004; 101: 6900 – 4.en_US
dc.identifier.citedreferencevan de Kerkhof PCM, Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 495 – 9.en_US
dc.identifier.citedreferenceGoodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004; 15: 14 – 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.2007.08037.x.pdf
Size:
156.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.